Shuichan Xu

发表

ERK1/2 MAP kinases in cell survival and apoptosis

Zhimin Lu, Zhimin Lu, Shuichan Xu, 2006, IUBMB life.

Substrate Recognition and Ubiquitination of SCFSkp2/Cks1 Ubiquitin-Protein Isopeptide Ligase*

M. Pagano, F. Mercurio, Shuichan Xu, 2007, Journal of Biological Chemistry.

A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase

Chin-Chun Lu, H. Handa, G. Lander, 2016, Nature.

Binding of JNK/SAPK to MEKK1 Is Regulated by Phosphorylation*

C. Slaughter, M. Cobb, Shuichan Xu, 2002, The Journal of Biological Chemistry.

An Allosteric Inhibitor of the Human Cdc34 Ubiquitin-Conjugating Enzyme

Mike Tyers, Xiaojing Tang, Abdallah Al-Hakim, 2011, Cell.

HTLV-I Tax Protein Binds to MEKK1 to Stimulate IκB Kinase Activity and NF-κB Activation

R. Gaynor, M. Cobb, M. Barbosa, 1998, Cell.

Protein Interacting C-Kinase 1 Modulates Surface Expression of P2Y6 Purinoreceptor, Actin Polymerization and Phagocytosis in Microglia

Shuichan Xu, N. Zhang, Yin Wang, 2015, Neurochemical Research.

Phase I trial of an oral TORC1/TORC2 inhibitor (CC-223) in advanced solid and hematologic cancers.

Suzanne F. Jones, R. Kelley, J. Bendell, 2012 .

Protein Interacting C-Kinase 1 Modulates Surface Expression of P2Y6 Purinoreceptor, Actin Polymerization and Phagocytosis in Microglia

Shuichan Xu, N. Zhang, Yin Wang, 2016, Neurochemical Research.

CC-115, a dual inhibitor of mTOR kinase and DNA-PK, blocks DNA damage repair pathways and selectively inhibits ATM-deficient cell growth in vitro

L. Sapinoso, T. Tsuji, L. Wong, 2017, Oncotarget.

MEKK1 Binds Directly to the c-Jun N-terminal Kinases/Stress-activated Protein Kinases*

M. Cobb, Shuichan Xu, 1997, The Journal of Biological Chemistry.

Phase I expansion trial of an oral TORC1/TORC2 inhibitor (CC-223) in advanced solid tumors.

T. Cloughesy, P. Mischel, J. Nemunaitis, 2013 .

Phase I expansion trial of an oral TORC1/TORC2 inhibitor (CC-223) in diffuse large B-cell lymphoma (DLBCL) and multiple myeloma (MM)

T. Meyer, L. Paz-Ares, P. Munster, 2013 .

CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization

P. Worland, Shuichan Xu, D. Mortensen, 2015, Molecular Cancer Therapeutics.

A phase I dose‐escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC‐223 in patients with advanced solid tumors or multiple myeloma

Suzanne F. Jones, Y. Liu, P. Mischel, 2015, Cancer.

The PHD domain of MEKK1 acts as an E3 ubiquitin ligase and mediates ubiquitination and degradation of ERK1/2.

T. Hunter, M. Cobb, C. Joazeiro, 2002, Molecular cell.

The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas

C. James, J. Heath, T. Cloughesy, 2013, Clinical Cancer Research.

Cancer Therapy : Preclinical The mTOR Kinase Inhibitors , CC 2141 and CC 2142 , Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas

C. James, J. Heath, T. Cloughesy, 2013 .

Synthetic Lethal Strategy Identifies a Potent and Selective TTK and CLK1/2 Inhibitor for Treatment of Triple-Negative Breast Cancer with a Compromised G1–S Checkpoint

D. Mikolon, Shuichan Xu, T. Shi, 2018, Molecular Cancer Therapeutics.

Phosphorylation and spindle pole body localization of the Cdc15p mitotic regulatory protein kinase in budding yeast

M. Latterich, T. Hunter, Han-kuei Huang, 2000, Current Biology.

Reconstitution of Mitogen-activated Protein Kinase Phosphorylation Cascades in Bacteria

M. Cobb, J. English, E. Schaefer, 1997, The Journal of Biological Chemistry.

NIK is a new Ste20‐related kinase that binds NCK and MEKK1 and activates the SAPK/JNK cascade via a conserved regulatory domain

Jiahuai Han, M. Cobb, Shuichan Xu, 1997, The EMBO journal.

Isolation of MEK5 and Differential Expression of Alternatively Spliced Forms *

M. Cobb, J. English, Shuichan Xu, 1995, The Journal of Biological Chemistry.

MAP kinase‐ and Rho‐dependent signals interact to regulate gene expression but not actin morphology in cardiac muscle cells

A. Thorburn, J. Thorburn, Shuichan Xu, 1997, The EMBO journal.

The Mitogen-Activated Protein Kinase p38-2 Is Necessary for the Inhibition of N-Type Calcium Current by Bradykinin

M. Cobb, M. Barbosa, Shuichan Xu, 1998, The Journal of Neuroscience.

MEKK1 Binds Raf-1 and the ERK2 Cascade Components*

M. Cobb, Shuichan Xu, S Xu, 2000, The Journal of Biological Chemistry.

MEKK1 Mediates the Ubiquitination and Degradation of c-Jun in Response to Osmotic Stress

T. Hunter, Zhimin Lu, Shuichan Xu, 2006, Molecular and Cellular Biology.

In vitro SCFbeta-Trcp1-mediated IkappaBalpha ubiquitination assay for high-throughput screen.

F. Mercurio, Shuichan Xu, D. Giegel, 2005, Methods in enzymology.

Actions of Rho family small G proteins and p21-activated protein kinases on mitogen-activated protein kinase family members

J. Frost, M. Cobb, Shuichan Xu, 1996, Molecular and cellular biology.

MEKK1 phosphorylates MEK1 and MEK2 but does not cause activation of mitogen-activated protein kinase.

J. Frost, M. Cobb, Shuichan Xu, 1995, Proceedings of the National Academy of Sciences of the United States of America.

MAP kinases ERK1 and ERK2: pleiotropic enzymes in a ubiquitous signaling network.

M. Cobb, D. Ebert, M. Cheng, 1994, Advances in cancer research.

CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization

P. Worland, Shuichan Xu, D. Mortensen, 2015, Molecular Cancer Therapeutics.